Compare GNPX & KUST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNPX | KUST |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.4M |
| IPO Year | 2017 | 2018 |
| Metric | GNPX | KUST |
|---|---|---|
| Price | $1.84 | $3.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 164.8K | 16.1K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,577,600.00 |
| Revenue This Year | N/A | $40.06 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.42 | $3.52 |
| 52 Week High | $9.99 | $224.00 |
| Indicator | GNPX | KUST |
|---|---|---|
| Relative Strength Index (RSI) | 23.85 | 44.42 |
| Support Level | $0.80 | N/A |
| Resistance Level | $2.12 | $4.13 |
| Average True Range (ATR) | 0.21 | 0.34 |
| MACD | -0.03 | -0.38 |
| Stochastic Oscillator | 4.39 | 7.04 |
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Kustom Entertainment Inc provides live event production and ticketing technology services. The company operates in two segments: video solutions and entertainment. The Video Solutions Segment represents the Company's legacy operations and includes the development, manufacture, and sale of digital video imaging and storage products, disinfectant, and related safety products for use in law enforcement, security, and commercial applications. The Entertainment Segment operates a secondary ticketing platform through TicketSmarter.com, acting as an intermediary between ticket buyers and sellers. In addition, this segment includes live event production and promotion activities, including the Country Stampede music festival and other entertainment events.